脑胶质瘤组织中胞质多聚腺苷酸化成分结合蛋白1、细胞周期蛋白B2的表达及临床意义  

Expression and Clinical Significance of Cytoplasmic Polyadenylation Element Binding Protein 1 and Cyclin B2 in Glioma Tissue

作　　者：祝展鹏 罗方接 张代龙 陈亚德 邓景阳 祝刚 ZHU Zhan-peng;LUO Fang-jie;ZHANG Dai-long;CHEN Ya-de;DENG Jing-yang;ZHU Gang(Graduate School of Guangdong Medical University,Zhanjiang,Guangdong,524023,China;Department of Neurosurgery,Dongguan Songshanhu Central Hospital,Dongguan,Guangdong,523200,China;Department of Neurosurgery,Huizhou Central People's Hospital,Huizhou,Guangdong,516001,China)

机构地区：[1]广东医科大学研究生院,广东湛江524023 [2]东莞松山湖中心医院神经外科,广东东莞523200 [3]惠州市中心人民医院神经外科,广东惠州516001

出　　处：《现代生物医学进展》2022年第1期168-172,共5页Progress in Modern Biomedicine

基　　金：广东省自然科学基金项目(2017A030313516)。

摘　　要：目的:检测脑胶质瘤组织中胞质多聚腺苷酸化成分结合蛋白1(CPEB1)、细胞周期蛋白B2(CCNB2)的表达,分析CPEB1、CCNB2表达与脑胶质瘤患者临床病理特征以及预后的关系。方法:选取2016年1月至2018年1月东莞松山湖中心医院神经外科收治的经手术切除的55例脑胶质瘤患者瘤组织标本(脑胶质瘤组)和50例颅脑损伤患者额叶或颞叶组织标本(对照组)。检测CPEB1、CCNB2表达,分析CPEB1、CCNB2表达与脑胶质瘤患者临床病理特征的关系。结合随访资料,采用Kaplan-Meier生存分析CPEB1、CCNB2阳性/阴性表达脑胶质瘤患者的预后差异及采用Cox比例风险回归分析其预后的影响因素。结果:脑胶质瘤组CPEB1、CCNB2阳性表达率均高于对照组(P<0.05)。肿瘤直径>2 cm、WHO分级Ⅲ级及远处转移的患者CCNB2阳性表达率高于肿瘤直径≤2 cm、WHO分级Ⅰ~Ⅱ级及无远处转移的患者(P<0.05);WHO分级Ⅲ级、远处转移患者的CPEB1阳性表达率高于WHO分级Ⅰ~Ⅱ级、无远处转移的患者(P<0.05)。CPEB1、CCNB2阳性表达患者3年生存率低于CPEB1、CCNB2阴性表达患者(P<0.05)。WHO分级Ⅲ级、CPEB1及CCNB2阳性表达是脑胶质瘤患者术后3年死亡的危险因素(P<0.05)。结论:脑胶质瘤组织中CPEB1、CCNB2的阳性表达率均升高,其与脑胶质瘤恶性生物学行为以及不良预后有关。Objective: To investigate the expression cytoplasmic polyadenylation element binding protein 1(CPEB1) and cyclin B2(CCNB2) in glioma tissue, and to analyze the relationship between the expression of CCNB2, CPEB1 and prognosis,clinicopathological features of glioma patients. Methods: Paraffin specimens of tumor tissue(glioma group) from 55 cases of glioma patients who underwent surgical resection in the Department of Neurosurgery, Dongguan Songshanhu Central Hospital from January2016 to January 2018 were collected and paraffin specimens of frontal lobe or temporal lobe tissue(control group) from 50 cases of craniocerebral injury patients who underwent surgical resection. The expression of CPEB1 and CCNB2 were detected, and the relationship between clinicopathological features and the expression of CPEB1, CCNB2 were analyzed. Kaplan Meier survival analysis was used to analyze the prognostic difference between positive and negative CPEB1 and CCNB2 expression and Cox proportional risk regression analysis of the prognostic factors were performed in combination with follow-up data. Results: The positive expression rate of CPEB1 and CCNB2 in glioma group were higher than those in control group(P<0.05). The positive expression rate of CCNB2 in patients with tumor diameter >2 cm, the WHO classification Ⅲ level, with distant metastasis were higher than those in patients with tumor diameter ≤2 cm, the WHO classification Ⅰ~Ⅱ level, without distant metastases(P<0.05). The positive expression rate of CPEB1 in patients with the WHO classification Ⅲ level, with distant metastasis were higher than those in the WHO classification Ⅰ~Ⅱ, without distant metastases(P<0.05). The 3-year survival rates of CPEB1 and CCNB2 positive expression patients were lower than thaose of CPEB1 and CCNB2 negative expression patients(P<0.05). The WHO classification Ⅲ level, CPEB1, CCNB2 positive expression were risk factors for death 3 years postoperatively in patients with glioma(P<0.05). Conclusion: The positive expressions of CPEB1 a

关 键 词：脑胶质瘤 胞质多聚腺苷酸化成分结合蛋白1 细胞周期蛋白B2 病理特征 预后 

分 类 号：R739.4[医药卫生—肿瘤]